Abstract 1730P
Background
A constellation of a large attack surface of interconnected devices and cyberimmaturity renders healthcare ripe to cybercrime. These vulnerabilities and their consequences will be magnified by the exponential growth in artificial intelligence. We assess the impact and implications of a cyberattack on a national cancer centre.
Methods
On 14 May 2021 (day 0), the first national healthcare ransomware attack occurred within which all hospitals including Cork University Hospital (CUH) Cancer Centre was implicated. Contingency plans were only present in laboratory services who had previously experience information technology (IT) failures. Departmental handwritten logs of activity and responses for 700 days after the attack were reviewed.
Results
Following the attack, all IT systems were shut down. No hospital cyberattack emergency plan was in place. Within CUH, on day 0, all radiotherapy (RT) treatment stopped, outpatient activity fell by 50%, and elective surgery stopped. Haematology, biochemistry and radiology capacity fell by 90% (daily sample deficit (DSD) 2700 samples), 75% (DSD 2,250 samples), and 90% (100% mammography/PETscan) respectively. Histopathology reporting times doubled (7 to 15 days). or paused IT links. Outsourcing of radiology and radiotherapy (RT) commenced, alternative communication networks (e.g., proton mail; Siilo) were utilised and national conference calls for RT and clinical trials were established. 136 patients had interrupted RT: median gap day 6 days category 1, 10 days for remaining patients. By day 28, e-mail communication was restored. By day 210, reporting and data storage backlogs were cleared and over 2000 computers were checked/replaced by the Irish Army. Notification of patients and staff whose data was compromised is ongoing (day 720).
Conclusions
Cyberattacks have rapid, profound and protracted impacts. While laboratory and diagnostic deficits were readily quantified, the impact of disrupted/delayed care on patient outcomes is less readily quantifiable but likely to be much greater. As criminals and nation states weaponize the internet, cyberawareness and cyberattack plans need to be embedded in healthcare.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
R.J. Keogh: Financial Interests, Other, Travel, Accommodations, Expenses: MSD. All other authors have declared no conflicts of interest.
Resources from the same session
1902P - Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC)
Presenter: Audreylie Lemelin
Session: Poster session 23
1903P - Tumor response by baseline metastases in patients (pts) with renal cell carcinoma (RCC) treated with lenvatinib (L) plus pembrolizumab (P) vs sunitinib (S): Post hoc analysis of the CLEAR trial
Presenter: Viktor Gruenwald
Session: Poster session 23
1904P - Treatment options and outcome of metastatic renal cell carcinoma patients with brain or bone metastases: A real-world evidence from a German retrospective multi-center analysis
Presenter: Pia Paffenholz
Session: Poster session 23
1905P - Heterogeneity in tertiary lymphoid structures predicts the distinct prognosis and immune microenvironment of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster session 23
1906P - Metastasized non-clear cell renal cell carcinoma: Which entities are dangerous? Results learned from reference pathology of the SuniForecast study
Presenter: Arndt Hartmann
Session: Poster session 23
1907P - Multi-omics mapping positions antigenic myeloid-T cell crosstalk at the core of advanced renal cell carcinoma (aRCC) response to immune checkpoint blockade (ICB)
Presenter: Lisa Kinget
Session: Poster session 23
1908P - Utility of circulating tumor (ct)DNA testing for molecular residual disease (MRD) detection and treatment response monitoring in patients (pts) with renal cell carcinoma (RCC)
Presenter: Michael Smigelski
Session: Poster session 23
1909P - Baseline cytokine levels according to the line of treatment in patients with metastatic clear cell renal cell carcinoma treated with nivolumab: NIVOREN GETUG-AFU 26 translational study
Presenter: Larissa Rainho
Session: Poster session 23
1910P - Evaluation of a genome-wide methylome enrichment platform for circulating tumor DNA quantification and prognostic performance in renal cell carcinoma (RCC)
Presenter: Brian Rini
Session: Poster session 23
1911P - Effect of VHL mutations on efficacy of immune checkpoint inhibitors in renal cell carcinoma
Presenter: Guojie Yu
Session: Poster session 23